The arrival of Retatrutide ZPHC, at a strength of 120mg, is generating considerable excitement within the medical community. This groundbreaking dual GIP and GLP-1 agonist medication seems to offer significant improvements in body reduction compared to previous therapies. Preliminary clinical tri